Moderna stock skidded on reports Robert F. Kennedy Jr. is considering pulling funding for its bird flu vaccine. Is MRNA stock ...

Despite high R&D spending and cash burn, Moderna aims for breakeven by 2028, driven by new vaccine opportunities. Explore ...

CEO Stephane Bancel has bought stock for the first time on the open market since he was named the top executive in October ...

Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...

Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...

For now, Moderna may be a good stock to put on a watch list, but it's likely too risky and volatile for the vast majority of ...

But in 2025, Moderna aims to reduce cash cost expenses by $1 billion, CEO Stéphane Bancel said at the J.P. Morgan Healthcare Conference in January. The company will report its 2024 full-year ...

Moderna has reported revenue of $1bn for the fourth quarter (Q4) of 2024 - a sharp decline from the $2.8bn recorded in the same quarter in 2023. The drop was largely attributed to the earlier launch ...

We recently published a list of 10 Firms Kick Off Shortened Trading Week With Impressive Gains. In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against firms ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved an mRNA respiratory syncytial virus (RSV) ...

Bancel said the company expects to have cut about $1 billion in costs by the end of this year, and said Moderna "anticipate multiple approvals" of new drugs starting in 2025. Sales Estimates Well ...

Our team successfully filed three Biologics License Applications in the final months of the year and reduced our costs by 27 percent compared to 2023,” said Stephane Bancel, CEO of Moderna (MRNA).